Related Experiment Video

Updated: May 16, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death

Suzana Assad Kahn1, Deborah Biasoli, Celina Garcia

  • 1Instituto de Ciências Biomédicas, CCS - Bloco F, Universidade Federal do Rio de Janeiro, 21949-590, Rio de Janeiro, Brazil.

Current Topics in Medicinal Chemistry
|November 22, 2012
PubMed

Insights

Equinatoxin II (EqTx-II), a sea anemone toxin, enhances chemotherapy for glioblastoma (GBM). This novel approach potentiates temozolomide and etoposide effectiveness, showing promise for improved GBM treatment with reduced side effects.

Area of Science:

  • Neuro-oncology
  • Pharmacology
  • Toxicology

Background:

  • Glioblastoma (GBM) presents significant treatment challenges due to inherent chemoresistance.
  • Current GBM therapies offer limited efficacy, necessitating innovative treatment strategies.
  • Understanding GBM resistance mechanisms is crucial for developing improved therapeutic approaches.

Purpose of the Study:

  • To investigate the potential of equinatoxin II (EqTx-II) in enhancing the efficacy of standard GBM chemotherapies.
  • To explore the underlying molecular mechanisms of EqTx-II's potentiating effect on GBM cells.
  • To evaluate the in vivo efficacy of combined EqTx-II and chemotherapy in a GBM model.

Main Methods:

  • Treatment of GBM cells with non-cytotoxic concentrations of EqTx-II in combination with temozolomide (TMZ) and etoposide (VP-16).
  • Assessment of cellular cytotoxicity and investigation of the PI3K/Akt signaling pathway.
  • In vivo studies using Magnetic Resonance Imaging (MRI) to monitor GBM tumor growth inhibition.

Main Results:

  • Non-cytotoxic EqTx-II significantly potentiated the cytotoxic effects of both TMZ and VP-16 on GBM cells.
  • The observed potentiation was selective to GBM cells and linked to PI3K/Akt pathway inhibition.
  • In vivo MRI demonstrated that EqTx-II enhanced VP-16's ability to inhibit GBM tumor growth.

Conclusions:

  • Combined therapy with EqTx-II and chemotherapy offers a promising new strategy for GBM treatment.
  • This approach may allow for lower doses of chemotherapeutic agents, potentially reducing adverse effects.
  • EqTx-II represents a valuable tool for enhancing the effectiveness of current GBM treatments.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...